Heart Attack News and Research

RSS

Chaos models may help predict cardiac arrhythmias, say researchers

Chaos models may someday help model cardiac arrhythmias -- abnormal electrical rhythms of the heart, say researchers in the journal CHAOS, which is published by the American Institute of Physics. In recent years, medical research has drawn more attention to chaos in cardiac dynamics. Although chaos marks the disorder of a dynamical system, locating the origin of chaos and watching it develop might allow researchers to predict, and maybe even counteract, certain outcomes.

22 Jul 2010

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

The VA Maryland Health Care System participated in a landmark national study of more than 10,251 high-risk diabetic adults across the nation, testing if three complementary treatment strategies can reduce the high rate of heart disease and stroke associated with type 2 diabetes and if these treatment strategies can also slow the progression of eye disease associated with diabetes, the leading cause of blindness in working-age Americans.

22 Jul 2010

WPI's workshop to include demonstrations on location, tracking and physiological monitoring systems

Worcester Polytechnic Institute, a leader in the development of technology for precisely locating, tracking, and monitoring first responders inside buildings, will host the fifth annual Workshop on Precision Indoor Personnel Location and Tracking Technology for Emergency Responders in the WPI Campus Center Aug. 2-3, 2010.

22 Jul 2010

First hospital in U.S. to use portable heart/lung machine

The Methodist Hospital is the first in the U.S. to use a portable heart/lung machine to move critically ill patients easily and safely to different areas of the hospital for medical tests or from outlying hospitals to the medical center for specialized treatment. Recently approved for use in the U.S. by the FDA, the device has been used in Europe since 2008 with excellent results.

21 Jul 2010

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Fero Industries, Inc. is pleased to provide these comments regarding the recent Food and Drug Administration advisory panel recommendation concerning the GlaxoSmithKline PLC diabetes drug Avandia. The FDA advisory panel has recommended that the agency keep diabetes drug Avandia on the U.S. market despite data clearly showing an increased risk of a heart attack and that GSK covered up their own research that first identified the problem.

20 Jul 2010

Scientists find major shortcomings in assessing CVD risk in HIV patients

At the same time that medical science has nearly eliminated AIDS deaths in patients treated for human immunodeficiency virus, two international meetings of HIV/AIDS scientists and patient advocates find major shortcomings in the design and analysis of studies used to assess cardiovascular disease risk in people with HIV with significant implications for improving medical care.

20 Jul 2010

Federal advisory panel with reservations, recommends keeping Avandia on the Market

Federal advisers delivered a mixed verdict Wednesday on the diabetes drug Avandia,with a significant number of experts voting to recommend that it be pulled from the market because of safety concerns but a majority urging to keep it available, perhaps with tough new restrictions and new warnings.Avandia was once the world's most popular diabetes drugs but has become the focus of intense debate because of concerns that it increases the risk for heart attacks and strokes.

16 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Research shows behavioral economic analysis may help understand role of craving in addictions

Just-published research led by a psychologist at the University of Georgia shows that behavioral economic analysis may lead to an improved understanding of craving for alcohol and other drugs. This method of studying how craving alters the way a person values a drug is fairly new, but according to the study, it may well help assess cravings more accurately and contribute to identifying more effective ways to defeat addictions.

15 Jul 2010

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

After two days of hearings, an advisory committee to the U.S. Food and Drug Administration (FDA) recommended that the FDA allow the type 2 diabetes drug rosiglitazone (brand name, Avandia), to stay on the market, but with most committee members suggesting that the label be revised to include increased warnings. Rosiglitazone is one in a class of drugs called thiazolidinediones (TZDs), used to treat type 2 diabetes.

15 Jul 2010

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.

15 Jul 2010

Genelex, Helix announce strategic alliance to increase availability of new DNA Drug Sensitivity Tests

Genelex and Helix have announced a personalized prescribing strategic alliance to increase the availability of important new DNA Drug Sensitivity Tests such as Plavitest and Tamoxitest. These tests and the GeneMedRx medication management software can save lives and healthcare dollars by allowing doctors to personalize their prescribing practices in order to prevent adverse medication outcomes, including treatment failures and dangerous side effects.

15 Jul 2010

Individual genes and networks that play an important role in inflammation, atherosclerosis identified

HemoShear, LLC, a leading developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds, has produced a profile of all of the genes that influence the biology and function of the human artery system. This research has generated valuable information on the entire spectrum of genes that are found in specific cell-types that make up human arteries.

14 Jul 2010

InQ Biosciences to launch fully integrated Cell Research System

InQ Biosciences, a provider of innovative technologies for cell growth and research, announced its plans to launch the InQ™ Cell Research System during the fourth quarter of 2010. InQ is the first fully integrated system that creates a high fidelity in vivo environment for studying stem cells, plus nerve, brain, and other mammalian cells for disease research.

14 Jul 2010

FDA to decide on Avandia’s fate Wednesday

Avandia, a drug used as a treatment for type 2 diabetes was approved for use in 1999. However controversies have surrounded it since 2007 when a Cleveland Clinic cardiologist Steven E. Nissen published a study in the acclaimed New England Journal of Medicine that concluded that the drug significantly increased the risk for heart problems like heart attacks, heart failure and deaths.

13 Jul 2010

Combined behavioral interventions most effective way to reduce heart disease risk

Combining counseling, extended follow-up with a healthcare provider and self-monitoring of diet and exercise is the most effective way to help patients embrace lifestyle changes that can lower their risk for heart and blood vessel (cardiovascular) diseases, according to a scientific statement published in Circulation: Journal of the American Heart Association.

13 Jul 2010

New approach in treating heart attack, cardiomyopathy using stem cells

Presenting at the UK National Stem Cell Network annual science conference today (13 July), Professor Michael Schneider describes a new approach to treating heart attack and cardiomyopathy using stem cells.

13 Jul 2010

Behavioral change programs help lower risk for cardiovascular diseases: Scientific statement

13 Jul 2010

Sleep apnea may increase risk of heart disease and death by 68%: Study

Obstructive sleep apnea (OSA) that leads to snoring and is actually caused by frequent collapse of the airway during sleep makes it difficult for sufferers to breathe for periods lasting as long as 10 seconds. Severe sufferers may have 30 such apnoeic or breathless episodes per hour that can severely disrupt sleep.

13 Jul 2010

Accumetrics, Daiichi Sankyo, Eli Lilly collaborate to raise awareness about antiplatelet therapy

Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that the companies have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of platelet function testing.

12 Jul 2010

Heart Attack News and Research

Chaos models may help predict cardiac arrhythmias, say researchers

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

WPI's workshop to include demonstrations on location, tracking and physiological monitoring systems

First hospital in U.S. to use portable heart/lung machine

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Scientists find major shortcomings in assessing CVD risk in HIV patients

Federal advisory panel with reservations, recommends keeping Avandia on the Market

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Research shows behavioral economic analysis may help understand role of craving in addictions

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

Genelex, Helix announce strategic alliance to increase availability of new DNA Drug Sensitivity Tests

Individual genes and networks that play an important role in inflammation, atherosclerosis identified

InQ Biosciences to launch fully integrated Cell Research System

FDA to decide on Avandia’s fate Wednesday

Combined behavioral interventions most effective way to reduce heart disease risk

New approach in treating heart attack, cardiomyopathy using stem cells

Behavioral change programs help lower risk for cardiovascular diseases: Scientific statement

Sleep apnea may increase risk of heart disease and death by 68%: Study

Accumetrics, Daiichi Sankyo, Eli Lilly collaborate to raise awareness about antiplatelet therapy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News